Using a syngeneic immunocompetent mouse model, Liao et al. observed that targeting lymphoma with IFNα abolished resistance of B-cell lymphoma to anti-CD20 Ab while also limiting interferon (IFN)-associated systemic toxicity in the host (Liao et al.2017). This evidence concerns the gene IFNA1 and B-cell non-Hodgkin lymphoma.